# Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

> **NCT05504239** · PHASE3 · COMPLETED · sponsor: **Handok Inc.** · enrollment: 235 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- **DRUG:** Teneligliptin Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT05504239
- **Lead sponsor:** Handok Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-27
- **Primary completion:** 2024-04-23
- **Final completion:** 2024-04-23
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05504239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05504239, "Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05504239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*